PF-04457845

DRUG6 trials

Sponsors

Pfizer, Yale University

Conditions

Cannabis DependenceFear ConditioningHealthy VolunteersOsteoarthritis, KneePost-Traumatic Stress DisorderTourette Syndrome

Early Phase 1

Cannabinoid Augmentation of Fear Response in Humans

CompletedNCT01665573

Yale UniversityFear Conditioning

Start: 2012-07-17End: 2015-10-16Updated: 2022-03-11

Phase 1

Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects

CompletedNCT00918164

PfizerHealthy Volunteers

Start: 2009-05-31End: 2009-07-31Updated: 2009-07-10

FAAH Inhibitor Trial for Adults With Tourette Syndrome

TerminatedNCT02134080

Yale UniversityTourette Syndrome

Start: 2014-05-31End: 2017-03-31Updated: 2018-10-29

Phase 2

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

CompletedNCT00981357

PfizerOsteoarthritis, Knee

Start: 2009-11-30End: 2010-05-31Updated: 2017-09-19

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

CompletedNCT01618656

Yale UniversityCannabis Dependence

Start: 2012-09-12End: 2016-03-11Updated: 2023-02-23

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

TerminatedNCT02216097

PfizerPost-Traumatic Stress Disorder

Start: 2014-10-31End: 2015-03-31Updated: 2016-06-29

Related Papers

Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.

2018-12-06127 citations